|Accueil||Recherche||Nouveautés||Email webmaster||Tous les textes - FMC||Sommaire général||Page précédente|
Sublingual immunotherapy for peanut allergy
A randomized, double-blind, placebo-controlled multicenter trial
The Journal of Allergy and Clinical Immunology. Volume 131, Issue 1 , Pages 119-127.e7, January 2013 [Lire]
David M. Fleischer, MD, A. Wesley Burks, MD, Brian P. Vickery, MD, Amy M. Scurlock, MD, Robert A. Wood,
MD, Stacie M. Jones, MD, Scott H. Sicherer, MD, Andrew H. Liu, MD, Donald Stablein, PhD, Alice K. Henning, MS,
Lloyd Mayer, MD, Robert Lindblad, MD, Marshall Plaut, MD, Hugh A. Sampson, MD, Consortium of Food Allergy Research
Allergie à l'arachide
Une nouvelle immunothérapie sublinguale
Pour cette nouvelle immunothérapie sublinguale (ISL), les patients doivent prendre quotidiennement le liquide à base de poudre d'arachide et le garder « sous la langue » durant 2 mn. L'étude conclut que cette immunothérapie sublinguale induit une désensibilisation dans la majorité des cas et de plus en plus avec la durée du traitement.
70% des participants ayant reçu l'ISL sont désensibilisés
mais 15% des participants ayant reçu le placebo, le sont aussi...
There are presently no available therapeutic options for patients with peanut allergy.
We sought to investigate the safety, efficacy, and immunologic effects of peanut sublingual immunotherapy (SLIT).
After a baseline oral food challenge (OFC) of up to 2 g of peanut powder (approximately 50% protein; median successfully consumed dose [SCD], 46 mg), 40 subjects, aged 12 to 37 years (median, 15 years), were randomized 1:1 across 5 sites to daily peanut or placebo SLIT. A 5-g OFC was performed after 44 weeks, followed by unblinding; placebo-treated subjects then crossed over to higher dose peanut SLIT, followed by a subsequent crossover Week 44 5-g OFC. Week 44 OFCs from both groups were compared with baseline OFCs; subjects successfully consuming 5 g or at least 10-fold more peanut powder than the baseline OFC threshold were considered responders.
After 44 weeks of SLIT, 14 (70%) of 20 subjects receiving peanut SLIT were responders compared with 3 (15%) of 20 subjects receiving placebo (P < .001). In peanut SLIT responders, median SCD increased from 3.5 to 496 mg. After 68 weeks of SLIT, median SCD significantly increased to 996 mg (compared with Week 44, P = .05). The median SCD at the Week 44 Crossover OFC was significantly higher than baseline (603 vs 71 mg, P = .02). Seven (44%) of 16 crossover subjects were responders; median SCD increased from 21 to 496 mg among responders. Of 10,855 peanut doses through the Week 44 OFCs, 63.1% were symptom free; excluding oral-pharyngeal symptoms, 95.2% were symptom free.
Peanut SLIT safely induced a modest level of desensitization in a majority of subjects compared with placebo. Longer duration of therapy showed statistically significant increases in the SCD.
|Accueil||Nouveautés||Email webmaster||Sommaire FMC||Sommaire général||Page précédente|